Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO- XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer [Accessibility Statement] Skip Navigation--Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)Vir Biotechnology- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of e ...